View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 8, 2021

UAE begins trials of Russia’s Sputnik V Covid-19 vaccine

The United Arab Emirates (UAE) has initiated clinical trials of Russia’s Sputnik V vaccine for Covid-19 as the number of cases surge in the country.

The United Arab Emirates (UAE) has initiated clinical trials of Russia’s Sputnik V vaccine for Covid-19 as the number of cases surge in the country.

Sputnik V was developed by the Ministry of Health of the Russian Federation’s Gamaleya Research Institute of Epidemiology and Microbiology.

The Phase III trials, which were announced last October, will enrol up to 500 participants in the initial stage, Reuters reported.

Healthy adults of various nationalities living in Abu Dhabi, who are neither previously infected with Covid-19 nor have been part of any Covid-19 vaccination trial, will be inoculated in these trials.

The participants will receive two doses of the vaccine, which will be administered 20 days apart, at a hospital in Abu Dhabi.

They will be followed up through regular visits and teleconsultations for 180 days after the treatment.

Data from the first two phases of the trial had shown that the subjects receiving Sputnik V vaccine had a stable humoral as well as cellular immune response and no serious adverse events were noted.

Separately, the UAE is carrying out Phase III trials of a vaccine developed by China National Pharmaceutical Group (Sinopharm).

As per the UAE health ministry, the vaccine is authorised in the country and is available for free on a priority basis to more vulnerable people.

Last month, the emirate of Dubai initiated vaccinating individuals with Pfizer and BioNTech’s vaccine.
As of 5 January, 826,301 vaccines had been administered to the people.

Furthermore, the UAE intends to inoculate over 50% of the population in the first quarter of this year.

In July last year, Sinopharm initiated a Phase III clinical trial to assess its Covid-19 vaccine candidate in Abu Dhabi, UAE.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU